自2020年以来,减重手术前的GLP-1药物猛增16倍,目前29%以上的患者使用。 GLP-1 drugs before weight-loss surgery surged 16-fold since 2020, now used by over 29% of patients.

自2020年以来,在减重手术前使用GLP-1药物的人数增加了16倍,到2024年底,超过29%的病人接受了此类药物治疗,而根据美国外科医生学会2025年会议对近365,000名病人进行的一项研究,这一比例低于2%。 Use of GLP-1 drugs before weight-loss surgery has surged 16-fold since 2020, with over 29% of patients receiving such medications by late 2024, up from under 2%, according to a study of nearly 365,000 patients presented at the American College of Surgeons’ 2025 meeting. 这一趋势表明,特别是在非糖尿病患者和糖尿病患者中,药理疗法与严重肥胖症手术相结合的趋势正在日益转变。 The trend reflects a growing shift toward combining pharmacotherapy and surgery for severe obesity, particularly among non-diabetic and diabetic patients. 研究人员注意到,这标志着多学科体重管理的新时代,尽管目前仍在研究最佳手术前用途。 Researchers note this marks a new era in multidisciplinary weight management, though optimal pre-surgical use remains under study. 调查结果是初步的,尚未经过同行审查。 Findings are preliminary and not yet peer-reviewed.